Figures computed from official regulatory filings — .
Ownershipinsiders 0.13% · institutions 56.51%
In EUR · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for DBV TECHNOLOGIES only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Market information source · Oct 19, 2026
Open-market timeline · full history
2 buys11 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Bpifrance Participations SAtrack record | Sell | $306.7K | AMF |
| Bpifrance Participations SAtrack record | Sell | $413.1K | AMF |
| Bpifrance Participations SAtrack record | Sell | $3.3M | AMF |
| Bpifrance Participations SAtrack record | Sell | $1M | AMF |
| Bpifrance Participations SAtrack record | Sell | $434K | AMF |
| Bpifrance Participations SAtrack record | Sell | $724.9K | AMF |
| Bpifrance Participations SAtrack record | Sell | $5.4M | AMF |
| Bpifrance Participations SAtrack record | Sell | $3.5M | AMF |
| Bpifrance Participations SAtrack record | Sell | $2.8M | AMF |
| Bpifrance Participations SAtrack record | Sell | $378.4K | AMF |
| Bpifrance Participations SAtrack record | ExerciseD (derivative) | $7M | AMF |
| Bpifrance Participations SAtrack record | Sell | $10.1M | AMF |
| Bpifrance Participations SAtrack record | Award | $4.5M | AMF |
| Daniel Tassé | Buy | $32.2K | conv 81First in 12mo | AMF |
| Daniel Soland | Buy | $48.7K | conv 36First in 12mo | AMF |
| Bpifrance Participations SAtrack record | Award | $7.9M | AMF |